ArticleJournal of cellular and molecular medicine2020
A five-mRNA signature associated with post-translational modifications can better predict recurrence and survival in cervical cancer.
Article in Journal of cellular and molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Transcriptomic identification and developmental mapping ofTurkish journal of biology = Turk biyoloji dergisi · 2026Article
- In Vitro Effects of Cabazitaxel and Menadione on Cell Growth, Metabolism, and Transcriptomic Profile of Human Prostate Cancer Cell Lines.Prostate cancer · 2026Article
- Differentially Expressed Genes Identify FIGO Stage II Cervical Cancer Patients with a Higher Risk of Relapse in a Small Cohort.Journal of personalized medicine · 2025Article
- Article
- Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment.Scientific reports · 2023Article
- Identifying a cervical cancer survival signature based on mRNA expression and genome-wide copy number variations.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Immune landscape and risk prediction based on pyroptosis-related molecular subtypes in triple-negative breast cancer.Frontiers in immunology · 2022Article
- A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.Frontiers in immunology · 2022Article
- Development and Validation of a Prognostic Classifier Based on Lipid Metabolism-Related Genes in Gastric Cancer.Frontiers in molecular biosciences · 2021Article
- A novel lncRNA-mRNA-miRNA signature predicts recurrence and disease-free survival in cervical cancer.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021Article
- Pan-Cancer Analysis of FURIN as a Potential Prognostic and Immunological Biomarker.Frontiers in molecular biosciences · 2021Article
- Construction of Gene Modules and Analysis of Prognostic Biomarkers for Cervical Cancer by Weighted Gene Co-Expression Network Analysis.Frontiers in oncology · 2021Article
- Identification of a Six-Gene Signature for Predicting the Overall Survival of Cervical Cancer Patients.OncoTargets and therapy · 2021Article
- Tumor infiltrating immune cells (TIICs) as a biomarker for prognosis benefits in patients with osteosarcoma.BMC cancer · 2020Article
- A five-mRNA signature associated with post-translational modifications can better predict recurrence and survival in cervical cancer.Journal of cellular and molecular medicine · 2020Article
- Development of a Predictive Immune-Related Gene Signature Associated With Hepatocellular Carcinoma Patient Prognosis.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High mortality of patients with cervical cancer (CC) stresses the imperative of prognostic biomarkers for CC patients. Additionally, the vital status of post-translational modifications (PTMs) in the progression of cancers has been reported by numerous researches. Therefore, the purpose of this research was to dig a prognostic signature correlated with PTMs for CC. We built a five-mRNA (GALNTL6, ARSE, DPAGT1, GANAB and FURIN) prognostic signature associated with PTMs to predict both disease-free survival (DFS) (hazard ratio [HR] = 3.967, 95% CI = 1.985-7.927; P < .001) and overall survival (HR = 2.092, 95% CI = 1.138-3.847; P = .018) for CC using data from The Cancer Genome Atlas database. Then, the robustness of the signature was validated using GSE44001 and the Human Protein Atlas (HPA) database. CIBERSORT algorithm analysis displayed that activated CD4 memory T cell was also an independent indicator for DFS (HR = 0.426, 95% CI = 0.186-0.978; P = .044) which could add additional prognostic value to the signature. Collectively, the PTM-related signature and activated CD4 memory T cell can provide new avenues for the prognostic predication of CC. These findings give further insights into effective treatment strategies for CC, providing opportunities for further experimental and clinical validations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.